Dr. Barnea’s discovery of PreImplantation Factor (PIF) led to founding BioIncept, LLC which develops PIF-based treatments and diagnostics ranging from fertility treatment to autoimmune modulation and transplant acceptance. As Chief Scientific Officer and under his leadership, the translational collaboration team he envisioned and solidified includes some of the world’s most respected scientists. BioIncept owns a world-wide patent estate. Successful First-in-Human, Fast-Track awarded university-sponsored clinical trial to assess PIF’s safety value as monotherapy was completed (NCT#02239562. PIF was awarded Orphan Drug Designation (ODD) from the FDA.
Dr. Barnea published over 150 peer-reviewed manuscripts and edited 4 specialty textbooks. In 1989, he received the Elkeles Prize ‘Scientist of the Year in Medicine’ from the Israel Health Ministry/Jewish National Fund. In 2012 he was awarded the Bratanov medal/prize of ISIR for his contribution to the development of Immunology. In 2016 Dr. Barnea was elected member of SMNH, Safe Motherhood Newborn Health committee of FIGO, the International Federation of Obstetricians and Gynaecologists.
Markku Seppala Ovidon Lecture
Successful embryo-maternal interface: from nature to clinic
Abstract to be published soon